熱門資訊> 正文
Evotec将以3亿美元现金加特许权使用费的价格将Just-Evotec Biologics图卢兹工厂出售给Sandoz，标志着转向资产更轻的模式
2025-07-30 14:54
- Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz
- Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines using Just - Evotec Biologics' advanced continuous manufacturing technology
- The deal terms include the purchase price of the site for around US$ 300 m in cash, and in addition will include further technology related consideration, future development revenues, milestones and product royalties
- Planned transaction marks major milestone in Evotec's strategy to create asset-lighter business model leveraging high-margin offerings, with Just - Evotec Biologics remaining core business for Evotec
- Transaction is expected to immediately improve Evotec's short-, mid-, and long-term revenue mix, profit margins, and capital efficiency
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
